argenex SE $ARGX Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC lowered its stake in shares of argenex SE (NASDAQ:ARGX) by 8.2% in the fourth quarter, HoldingsChannel reports. The firm owned 22,500 shares of the company’s stock after selling 2,003 shares during the quarter. Natixis Advisors LLC’s holdings in argenex were worth $18,921,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. boosted its position in argenex by 2.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after purchasing an additional 12 shares during the period. Valeo Financial Advisors LLC boosted its position in argenex by 0.9% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after purchasing an additional 12 shares during the period. Sound View Wealth Advisors Group LLC boosted its position in argenex by 3.4% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock valued at $292,000 after purchasing an additional 13 shares during the period. Allworth Financial LP boosted its position in argenex by 12.7% during the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after purchasing an additional 13 shares during the period. Finally, Portside Wealth Group LLC boosted its position in argenex by 2.8% during the 3rd quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock valued at $430,000 after purchasing an additional 16 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Trading Up 5.8%

Shares of ARGX opened at $891.32 on Friday. The business’s 50-day moving average price is $794.90 and its 200 day moving average price is $813.42. The stock has a market capitalization of $55.43 billion, a P/E ratio of 39.68, a P/E/G ratio of 1.29 and a beta of 0.47. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The firm had revenue of $1.31 billion for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, research analysts predict that argenex SE will post 26.19 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on ARGX. Robert W. Baird boosted their price target on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. Wells Fargo & Company boosted their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Citizens Jmp boosted their price target on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research report on Friday, February 27th. Oppenheimer reduced their price target on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Finally, Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,019.50.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.